Skip to content
OpenCapital
Get started

National Research Corporation NRC Cash & Equivalents

Cash & Equivalents at other companies

HealthStream logo
HealthStreamHSTM
$48.71M-37.0%
Huron Consulting Group logo
Huron Consulting GroupHURN
$26.46M+13.2%
Doximity logo
DoximityDOCS
$219.18M+4.6%
TruBridge, Inc. logo
TruBridge, Inc.TBRG
$35.42M+250%
Hinge Health, Inc. logo
Hinge Health, Inc.HNGE
$188.11M-35.2%
Solventum logo
SolventumSOLV
$561M+5.1%

Other financials

Income statement

See full
Revenue$34.8M+3.7%
Operating income$5.6M-35.8%
Net income$3.2M+11.1%
EPS (diluted)$12.50+4,708%

Balance sheet

See full
Total debt$74.0M+26.2%
Total equity$13.5M-54.5%
Total assets$134.6M-0.5%

Cash flow

See full
Operating cash flow$7.2M+8.0%
CapEx$1.8M-38.6%
Free cash flow$5.3M+46.1%

Valuation

See full
Market cap$462.9M+22.8%
Enterprise value$534.37M+23.3%
P/E38.8×+21.3×
P/S3.3×+0.7×

Profitability

See full
Operating margin16.4%-8.2pp
Net margin8.6%-6.6pp
FCF margin12.6%+2.0pp

Returns & leverage

See full
Return on equity55.2%-9.3pp
Debt / equity5.5×+3.5×
Current ratio0.5×0.0×

Where this comes from

Reported directly by National Research Corporation in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: National Research Corporation’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about National Research Corporation's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is National Research Corporation's cash & equivalents?
National Research Corporation (NRC) reported cash & equivalents of $2.55M in Q1 2026.
How has National Research Corporation's cash & equivalents changed year-over-year?
National Research Corporation's cash & equivalents increased by 1.8% year-over-year, from $2.5M to $2.55M.
What is the long-term trend for National Research Corporation's cash & equivalents?
Over 5 years (2020 to 2025), National Research Corporation's cash & equivalents has grown at a -34.6% compound annual growth rate (CAGR), from $34.69M to $4.14M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.